Compare XBIT & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | QUAD |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 396.6M |
| IPO Year | 2015 | 2010 |
| Metric | XBIT | QUAD |
|---|---|---|
| Price | $2.43 | $7.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.93 |
| AVG Volume (30 Days) | 20.1K | ★ 212.1K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.71% |
| EPS Growth | N/A | ★ 150.47 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $2,419,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $57.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $5.01 |
| 52 Week High | $3.61 | $8.64 |
| Indicator | XBIT | QUAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 51.81 |
| Support Level | $2.35 | $6.38 |
| Resistance Level | $2.49 | $7.52 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 42.86 | 67.86 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..